AngioDynamics, Inc.
AngioDynamics, Inc. (ANGO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ango · pe ratio · data through May 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for AngioDynamics, Inc. (ANGO) measures how much investors pay for each dollar of the company's trailing earnings. ANGO's current PE ratio of N/A is calculated by dividing its stock price of $11.93 by its TTM earnings per share of -$0.75.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-05-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%41.0x
MedianQ3 · 75%214.5x
Max
At N/A, ANGO's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
AngioDynamics, Inc.You ANGO | $493M | N/A | — | -$0.75 |
 Cullinan Therapeutics, Inc. CGEM | $816M | N/A | — | -$3.72 |
 Fulcrum Therapeutics, Inc. FULC | $186M | N/A | — | -$1.18 |
 Standard BioTools Inc. LAB | $314M | N/A | — | -$0.20 |
 Neumora Therapeutics, Inc. Common Stock NMRA | $300M | N/A | — | -$1.45 |
 Ocugen, Inc. OCGN | $427M | N/A | — | -$0.23 |
 Omeros Corporation OMER | $713M | N/A | — | -$0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-05-31Latest FY2025 | — | $-0.83 | — | |
2024-05-31 FY2024 | — | $-4.59 | — | |
2023-05-31 FY2023 | — | $-1.33 | — | |
2022-05-31 FY2022 | — | $-0.68 | — | |
2021-05-31 FY2021 | — | $-0.82 | — | |
2020-05-31 FY2020 | — | $-4.39 | — | |
2019-05-31 FY2019 | 11.48x | $1.64 | -75.9% | |
2018-05-31 FY2018 | 47.73x | $0.44 | — | |
2017-05-31 FY2017 | — | $-0.19 | — | |
2016-05-31 FY2016 | — | $-1.21 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for AngioDynamics, Inc. (ANGO) measures how much investors pay for each dollar of the company's trailing earnings. ANGO's current PE ratio of N/A is calculated by dividing its stock price of $11.93 by its TTM earnings per share of -$0.75.
Frequently asked questions
ANGO pe ratio · 6 questionsANGO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.93 and TTM EPS of -$0.75. Data sourced from Financial Modeling Prep via ANGO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AngioDynamics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08